Faeth reports positive preliminary Phase 2 results for PIKTOR in endometrial cancer
FROM THE WIRE · BUSINESSWIRE.COM
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive preliminary Phase 2 data for an oncology candidate, with potential relevance for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FTH-PIK-201 trial evaluates PIKTOR with paclitaxel.
- 02Treatment targets patients with advanced endometrioid endometrial cancer and a PAM pathway mutation.
- 03The release reports positive preliminary topline data.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets